Last checked at 10 Jun 2022 12:21
10 June 2022
VENTURE LIFE GROUP PLC
("Venture Life", "VLG" or the "Company")
Director/PDMR Shareholding
Venture Life Group plc (AIM: VLG), a leader in developing, manufacturing and commercialising products for the international self-care market, announces that Paul McGreevy, Non-Executive Chairman, today purchased 138,571 ordinary shares of 0.3p each in the Company ("Ordinary Shares") at 35 pence per Ordinary Share.
Following this purchase, Mr Mcgreevy beneficially holds 287,439 Ordinary Shares representing approximately 0.23 per cent. of the Company's issued share capital.
For further information, please contact:
Venture Life Group PLC +44 (0) 1344 578004
Jerry Randall, Chief Executive Officer
Daniel Wells, Chief Financial Officer
Cenkos Securities plc (Nomad and Joint Broker) +44 (0) 20 7397 8900
Stephen Keys / Camilla Hume (Corporate Finance)
Russell Kerr / Michael Johnson (Sales)
Singer Capital Markets (Joint Broker)
Shaun Dobson / Alaina Wong (Corporate Finance) +44 (0) 20 74963000
Jonathan Dighe (Sales)
About Venture Life (www.venture-life.com)
Venture Life is an international consumer self-care company focused on developing, manufacturing and commercialising products for the global self-care market. With operations in the UK, Italy, The Netherlands and Sweden, the Group's product portfolio includes some key products such as the UltraDEX and Dentyl oral care product ranges, the Balance Activ range in the area of women's intimate healthcare, the Lift and Glucogel product ranges for hypoglycaemia, Gelclair and Pomi-T for oncology support, products for fungal infections and proctology, and dermo-cosmetics for addressing the signs of ageing. Its products are sold in over 90 countries worldwide.
The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies and grocery multiples. In the UK and The Netherlands these are supplied direct by the company to retailers, elsewhere they are supplied by the Group's international distribution partners.
Through its two Development & Manufacturing operations in Italy and Sweden, the Group also provides development and manufacturing services to companies in the medical devices and cosmetic sectors.
The Company makes the following disclosures in accordance with article 19(3) of the Market Abuse Regulation:
1
| Details of the person discharging managerial responsibilities / person closely associated
| |||||||
a)
| Name
| Paul McGreevy
| ||||||
2
| Reason for the notification
| |||||||
a)
| Position/status
| Non-Executive Chairman | ||||||
b)
| Initial notification /Amendment
| Initial notification | ||||||
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| |||||||
a)
| Name
| Venture Life Group plc | ||||||
b)
| LEI
| 213800S8CZUPLAB2KC70 | ||||||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| |||||||
a)
| Description of the financial instrument, type of instrument
Identification code
| Ordinary Shares of 0.3p each in Venture Life Group plc
GB00BFPM8908 | ||||||
b)
| Nature of the transaction
| Purchase of ordinary shares | ||||||
c)
| Price(s) and volume(s)
|
| ||||||
d)
| Aggregated information
- Aggregated volume
- Price
| 138,571 Ordinary Shares at a volume weighted average price of 35.00 pence per Ordinary Share
| ||||||
e)
| Date of the transaction
| 10 June 2022 | ||||||
f)
| Place of the transaction
| London Stock Exchange
| ||||||